Transurethral Vapor Ablation of Intermediate Risk Localized Prostate Cancer (PCa). Journal of Endourology, 2022

Purpose: Targeted and precise application of thermal energy stored in sterile water vapor is a novel approach to treat cancerous prostate tissue. We report safety and oncological results of transurethral hemigland vapor ablation in a prospective, single-arm study in men with unilateral, intermediate-risk localized prostate cancer.

Christopher M. Dixon, Richard M. Levin, Christopher H. Cantrill, Mikhail Regelman, Benjamin Spilseth, Ronald F. Tutrone Jr., Michael A. White, Aaron J. Milbank, Christopher A. Warlick

Access The Publication

websites2025-10-30T16:59:00-05:00September 2nd, 2025|Evidence|

The Vanquish^® Water Vapor Ablation System has been cleared as a tool for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.

Federal law (USA) restricts this device to sale by or on the order of a physician.

Refer to the device User Manual for a list of contraindications, warnings, and cautions.

Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.

1. Taneja, S., George, A, (2025, October 9-11). Thermal Water Therapy for The Management of Prostate Cancer: The VAPOR 2 Study: Initial Report Poster]. FOCAL+ Therapy Conference, Washington, DC, United States. https://focalcme.com/

Share This Post